Recent Posts in FDA Prescription Drugs Category
Posted on Nov 3, 2012 By Napoli Bern Ripka Shkolnik, LLP
Just a month ago, the focus on fungal meningitis, a rare but potentially deadly infection, was virtually nonexistent. Today it is receiving attention across the United States after an outbreak that ...
Continue reading "What is fungal meningitis?" »
Posted on Oct 30, 2012 By Napoli Bern Ripka Shkolnik, LLP
According to estimates from the Centers for Disease Control and Prevention (CDC) and state health departments, approximately 14,000 patients may have received injections from the three contaminated ...
Continue reading "14,000 Patients May Have Received Injections from Affected Lots of Steroid Injections Linked to Meningitis Outbreak" »
Posted on Oct 29, 2012 By Napoli Bern Ripka Shkolnik, LLP
With a 10th death reported in Tennessee, the death toll related to the fungal meningitis outbreak has reached 25. The latest report from the Centers for Disease Control and Prevention (CDC) is that ...
Continue reading "Meningitis Outbreak Claims 25 Lives, According to Latest CDC Update" »
Posted on Oct 29, 2012 By Napoli Bern Ripka Shkolnik, LLP
In a report released on October 26, the Food and Drug Administration (FDA) discussed conditions investigators observed at the New England Compounding Center (NECC), the pharmacy that has been linked ...
Continue reading "FDA Confirms Contamination in Pharmacy Linked to Fungal Meningitis Outbreak" »
Posted on Oct 29, 2012 By Napoli Bern Ripka Shkolnik, LLP
When a drug company wishes to sell a prescription drug in the United States, it must first get approval from the U.S. Food and Drug Administration (FDA). The FDA works to protect and promote public ...
Continue reading "How are new drugs approved by the FDA?" »
Posted on Oct 25, 2012 By Napoli Bern Ripka Shkolnik, LLP
According to the latest update from the U.S. Centers for Disease Control and Prevention (CDC) as of today, October 25, 2012, the current case count in the multistate fungal meningitis outbreak has ...
Continue reading "Latest CDC report on meningitis outbreak: 328 cases in 18 states" »
Posted on Oct 25, 2012 By Napoli Bern Ripka Shkolnik, LLP
Just two days ago, the Food and Drug Administration (FDA) released a list of facilities that had received products from the New England Compounding Center (NECC) that were shipped on or after May 21, ...
Continue reading "FDA releases 73-page list of New England Compounding Center customers" »
Posted on Oct 8, 2012 By Napoli Bern Ripka Shkolnik, LLP
Though originally approved by the Food and Drug Administration (FDA) in December of 2006, Budeprion XL 300 mg is now being recalled. The generic equivalent of Wellbutrin XL 300 mg, Budeprion was ...
Continue reading "FDA requests recall of Budeprion XL, generic equivalent of Wellbutrin" »
Posted on Sep 6, 2012 By Napoli Bern Ripka Shkolnik, LLP
The Food and Drug Administration (FDA) is known as a regulator of the pharmaceutical industry, working to protect the public by ensuring the safety and effectiveness of prescription and ...
Continue reading "FDA faces lawsuit regarding Alzheimer's drug" »
Posted on Aug 28, 2012 By Napoli Bern Ripka Shkolnik, LLP
Pioglitazone, previously only marketed as Actos by Takeda Pharmaceuticals, has now been approved by the Food and Drug Administration (FDA). This generic version of the antidiabetic drug is chemically ...
Continue reading "FDA approves generic version of Actos" »
Posted on Aug 15, 2012 By Napoli Bern Ripka Shkolnik, LLP
For over a decade, obese Americans have had limited options when it comes to FDA-approved weight loss medications that are seen as relatively safe. This trend may be linked to the rise and fall of ...
Continue reading "FDA approves second weight loss drug in two months" »
Posted on Jul 30, 2012 By Napoli Bern Ripka Shkolnik, LLP
Auxilium Pharmacueticals Inc manufactures Xiaflex, a drug approved in early 2010 by the Food and Drug Administration (FDA) for the treatment of Dupuytren's contracture, a medical condition ...
Continue reading "Auxilium Pharmaceuticals shares fall 3 percent after releasing data on Xiaflex study" »
Posted on Jun 25, 2012 By Marc J. Bern
A new study has found that use of a commonly prescribed high blood pressure medication is associated with severe gastrointestinal symptoms that mimic celiac disease, possibly leading to misdiagnosis ...
Continue reading "People on common blood pressure drug may be misdiagnosed, unnecessarily treated for celiac disease" »
Posted on May 23, 2012 By Marc J. Bern
The Food and Drug Administration (FDA) has issued a warning related to Hospira drug products, which may contain incorrect drug dosages as the result of a manufacturing error at the facility. Hospira, ...
Continue reading "FDA warns of overdose risk from overfilled Hospira Carpuject® syringe cartridges" »
Posted on May 14, 2012 By Napoli Bern Ripka Shkolnik, LLP
A new study has revealed that vaginal ring and transdermal patch contraceptives may present a higher risk of clotting in women who use these forms of birth control as opposed to certain oral ...
Continue reading "Transdermal patch and vaginal ring contraceptives present higher risk of blood clots, according to a new study" »
Posted on Apr 6, 2012 By Napoli Bern Ripka Shkolnik, LLP
A new study has linked Depo-Provera®, an injectable contraceptive, with an increased risk of breast cancer. The study, conducted by researchers at the Fred Hutchinson Cancer Research Center, ...
Continue reading "New study shows injectable contraceptive Depo-Provera® may double risk of breast cancer" »
Posted on Jan 9, 2012 By Marc J. Bern
Novartis Consumer Health, Inc. has issued a warning and recall after an issue at a production facility may have caused commingling of prescription and over-the-counter medications. Novartis has ...
Continue reading "Plant mix-up leads to recall of Excedrin, Gas-X, Bufferin and NoDoz" »